+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Preimplantation Genetic Diagnosis (PGD) - Global Strategic Business Report

  • PDF Icon

    Report

  • 173 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140180
The global market for Preimplantation Genetic Diagnosis (PGD) was estimated at US$114.9 Million in 2023 and is projected to reach US$160.4 Million by 2030, growing at a CAGR of 4.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Preimplantation Genetic Diagnosis (PGD): Safeguarding Genetic Health

Preimplantation genetic diagnosis (PGD) is a specialized procedure used in conjunction with in vitro fertilization (IVF) to screen embryos for genetic abnormalities before they are implanted in the uterus. This technique allows couples with a history of genetic disorders or chromosomal abnormalities to reduce the risk of passing these conditions on to their offspring. PGD involves the biopsy of one or more cells from a developing embryo, typically on the third or fifth day after fertilization, followed by genetic analysis to detect specific mutations or chromosomal abnormalities. Only embryos that are free of genetic defects are selected for implantation, increasing the likelihood of a healthy pregnancy and reducing the risk of genetic diseases. PGD is particularly valuable for couples who are carriers of hereditary conditions such as cystic fibrosis, Huntington's disease, or sickle cell anemia, as it provides an additional layer of assurance in the reproductive process.

How Are Technological Advancements Enhancing Preimplantation Genetic Diagnosis (PGD)?

Technological advancements have significantly improved the accuracy, reliability, and scope of preimplantation genetic diagnosis (PGD). The advent of next-generation sequencing (NGS) has revolutionized PGD by allowing comprehensive analysis of the entire genome, enabling the detection of a broader range of genetic abnormalities with greater precision. This technology has also reduced the time required for genetic analysis, allowing for faster decision-making in the IVF process. The development of more sophisticated biopsy techniques, such as trophectoderm biopsy on day five embryos, has increased the safety and effectiveness of PGD, minimizing the risk of harm to the embryo while providing a larger and more representative sample for analysis. Additionally, advances in bioinformatics and data analysis have enhanced the interpretation of genetic data, providing more accurate and detailed insights into the genetic health of embryos. These technological improvements have expanded the applications of PGD, making it a more powerful tool for ensuring the genetic health of future generations.

What Are the Key Applications and Benefits of Preimplantation Genetic Diagnosis (PGD)?

Preimplantation genetic diagnosis (PGD) is used in various reproductive scenarios, offering numerous benefits that enhance the likelihood of a healthy pregnancy and reduce the risk of genetic disorders. In cases where one or both parents are carriers of a known genetic mutation, PGD allows for the selection of embryos that do not carry the mutation, significantly reducing the risk of passing the condition on to the child. PGD is also used in cases of recurrent pregnancy loss, where it helps identify embryos with chromosomal abnormalities that are less likely to result in a successful pregnancy. Additionally, PGD is valuable for older women undergoing IVF, as it can screen for age-related chromosomal abnormalities, such as Down syndrome, improving the chances of a healthy pregnancy. The primary benefits of PGD include its ability to reduce the risk of genetic diseases, increase the success rate of IVF, and provide peace of mind to prospective parents. By allowing for the selection of genetically healthy embryos, PGD enhances the reproductive process and contributes to the long-term health of future generations.

What Factors Are Driving the Growth in the Preimplantation Genetic Diagnosis (PGD) Market?

The growth in the preimplantation genetic diagnosis (PGD) market is driven by several factors. The increasing prevalence of genetic disorders and the growing awareness of the benefits of genetic screening in reproductive health are significant drivers. Technological advancements that improve the accuracy, safety, and accessibility of PGD are also propelling market growth. The rising demand for IVF procedures, particularly among older women and couples with a history of genetic disorders, is further boosting the adoption of PGD. Additionally, the expansion of genetic counseling services, which guide couples through the PGD process, is contributing to market growth. The increasing availability of advanced genetic testing technologies and the growing focus on personalized medicine are further driving the market. These factors, combined with the continuous innovation in reproductive genetics, are driving the sustained growth of the PGD market.
 

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Chromosomal Abnormalities segment, which is expected to reach US$33.6 Million by 2030 with a CAGR of a 4.2%. The Aneuploidy segment is also set to grow at 4.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $30.6 Million in 2023, and China, forecasted to grow at an impressive 7.2% CAGR to reach $34.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Preimplantation Genetic Diagnosis (PGD) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preimplantation Genetic Diagnosis (PGD) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Preimplantation Genetic Diagnosis (PGD) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Preimplantation Genetic Diagnosis (PGD) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand for Genetic Disease Prevention Drives Market Growth
  • Technological Advancements in Genetic Testing Propel Market Dynamics
  • Increasing Awareness of Reproductive Health and Genetic Disorders Expands Addressable Market
  • Growing Adoption of In-vitro Fertilization (IVF) Techniques Throws the Spotlight on PGD
  • Focus on Reducing Risk of Genetic Disorders Enhances Market Prospects
  • Increasing Number of Fertility Clinics and Genetic Counseling Centers Boosts Market Reach
  • Expansion of Personalized Medicine and Precision Healthcare Sustains Market Growth
  • Rising Demand for Gender Selection and Family Balancing Accelerates Market Dynamics
  • Growing Awareness of Late Maternal Age and Associated Risks Spurs Market Demand
  • Collaborations between Research Institutes and Healthcare Providers Generate Innovation
  • Advancements in Genomic Technologies and Bioinformatics Propel Market Expansion
  • Focus on Ethical and Regulatory Compliance Enhances Market Opportunities
  • Increasing Healthcare Expenditure and Insurance Coverage Expands Market Reach
  • Rising Number of Fertility Treatments and Success Rates Boost Market Prospects
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Chromosomal Abnormalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Chromosomal Abnormalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Aneuploidy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Aneuploidy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for X-linked Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for X-linked Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 10: World 7-Year Perspective for Single Gene Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for HLA Typing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 12: World 7-Year Perspective for HLA Typing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Gender selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 14: World 7-Year Perspective for Gender selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Other PGD Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 16: World 7-Year Perspective for Other PGD Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
  • TABLE 17: World Preimplantation Genetic Diagnosis (PGD) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 19: USA 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
JAPAN
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 22: Japan Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Japan 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
CHINA
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 24: China Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 25: China 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
EUROPE
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 28: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
FRANCE
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 30: France Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 31: France 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
GERMANY
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
ITALY
  • TABLE 34: Italy Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Italy 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
UNITED KINGDOM
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 36: UK Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 37: UK 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
SPAIN
  • TABLE 38: Spain Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Spain 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
RUSSIA
  • TABLE 40: Russia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 41: Russia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
REST OF EUROPE
  • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 43: Rest of Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
ASIA-PACIFIC
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
  • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
AUSTRALIA
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 48: Australia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Australia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
INDIA
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 50: India Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: India 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
SOUTH KOREA
  • TABLE 52: South Korea Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 53: South Korea 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
REST OF ASIA-PACIFIC
  • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
LATIN AMERICA
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 56: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 57: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
  • TABLE 58: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
ARGENTINA
  • TABLE 60: Argentina Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Argentina 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
BRAZIL
  • TABLE 62: Brazil Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Brazil 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
MEXICO
  • TABLE 64: Mexico Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Mexico 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
REST OF LATIN AMERICA
  • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Rest of Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
MIDDLE EAST
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 68: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 69: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
  • TABLE 70: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 71: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
IRAN
  • TABLE 72: Iran Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 73: Iran 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
ISRAEL
  • TABLE 74: Israel Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Israel 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
SAUDI ARABIA
  • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 77: Saudi Arabia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
UNITED ARAB EMIRATES
  • TABLE 78: UAE Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 79: UAE 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
REST OF MIDDLE EAST
  • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
AFRICA
  • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 82: Africa Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 83: Africa 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

Table Information